Cost of biologic treatment persistence or switching in rheumatoid arthritis.

CONCLUSIONS: Patients with RA who switched biologic therapy incurred higher 1-year total postswitch healthcare costs compared with patients who were persistent on the index biologic. Healthcare costs were lowest for patients who started on etanercept, particularly those who persisted on etanercept. PMID: 30020745 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30020745?dopt=Abstract

Source: The American Journal of Managed Care - July 1, 2018 Category: Health Management Authors: Gu T, Mutebi A, Stolshek BS, Tan H Tags: Am J Manag Care Source Type: research